The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.
1. Whole blood platelet aggregation was measured by electrical impedance in 28 controls and 28 patients with primary Raynaud's phenomenon. 2. The patients were entered into a double-blind, placebo-controlled cross-over trial of the calcium antagonist nisoldipine, in which they received, in random order, three, 4 week treatments with placebo and nisoldipine (5 and 10 mg day-1). 3. Platelet aggregation responses to two concentrations (5.0 and 0.5 micrograms ml-1) of collagen were determined before treatment and at the end of each treatment phase. 4. There were no differences in aggregation response to either collagen concentration between controls and patients with primary Raynaud's phenomenon, or between placebo and active treatment phases. 5. These data do not support the suggestion that nisoldipine has a significant anti-platelet effect.
Francis
J L
JL
University Department of Haematology, Southampton General Hospital.
Roath
O S
OS
Challenor
V F
VF
Waller
D G
DG
D000328:Adult; D000368:Aged; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000494:pharmacology; D015737:Nisoldipine; D010974:Platelet Aggregation / Q000187:drug effects*; D011928:Raynaud Disease / Q000097:blood*
D002121:Calcium Channel Blockers; D015737:Nisoldipine; D009543:Nifedipine